Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AREDIA vs BONIVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
Hypercalcemia of malignancy,Osteolytic bone metastases of breast cancer,Osteolytic lesions of multiple myeloma,Paget's disease of bone (off-label)
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis
90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
Multiphasic; terminal half-life is approximately 300 hours (range 200-400 hours) reflecting slow release from bone. Clinically, this results in prolonged suppression of bone resorption lasting weeks after a single dose.
Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
Not metabolized; excreted unchanged in urine.
Not metabolized; excreted unchanged by the kidneys.
Primarily eliminated unchanged via renal excretion (about 30-40% of administered dose within 24 hours); remainder sequestered in bone and slowly released over months. Biliary/fecal excretion is negligible (<1%).
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
Approximately 54% bound to plasma proteins, primarily albumin.
~85-90% bound to plasma proteins, primarily albumin.
Steady-state Vd is approximately 0.4-0.6 L/kg, indicating extensive distribution to bone and soft tissues; rapid uptake by bone mineral.
Vd: 0.9-1.3 L/kg, indicating extensive distribution into bone and soft tissues.
Intravenous: 100% (only route). Oral bioavailability is <1% and clinically irrelevant; no oral formulation available.
Oral: 0.63% (fasting state); reduced to ~0.4% with food.
For Cr Cl >50 m L/min: no adjustment; Cr Cl 30-50 m L/min: reduce dose to 60 mg; Cr Cl <30 m L/min: not recommended (no data).
Contraindicated if Cr Cl < 30 m L/min. No adjustment for Cr Cl ≥ 30 m L/min. For Cr Cl 30-49 m L/min: avoid use due to lack of data; per FDA labeling, not recommended. For severe renal impairment (Cr Cl < 30): do not use.
No specific adjustment recommended; use caution in severe hepatic impairment due to limited data.
No specific adjustment required for hepatic impairment. Drug is not extensively metabolized by liver; pharmacokinetics unchanged in mild-to-moderate hepatic impairment. No data for severe hepatic impairment.
Safety and efficacy not established for pediatric patients.
Not approved for pediatric use. Safety and efficacy in patients < 18 years have not been established.
No specific dose adjustment required; monitor renal function and fluid status carefully owing to age-related decreased glomerular filtration rate.
No dose adjustment necessary based on age alone. Monitor renal function (Cr Cl) as elderly more likely to have decreased renal function; contraindicated if Cr Cl < 30 m L/min. Ensure adequate calcium and vitamin D intake.
None
None.
Renal impairment,Osteonecrosis of the jaw,Hypocalcemia,Severe musculoskeletal pain,Atypical femur fractures
Hypocalcemia must be corrected before therapy,Renal impairment: not recommended if Cr Cl <30 m L/min,Osteonecrosis of the jaw (ONJ),Atypical femur fractures,Severe musculoskeletal pain
Hypersensitivity to pamidronate or other bisphosphonates,Hypocalcemia
Hypersensitivity to ibandronate or any component,Hypocalcemia,Inability to stand or sit upright for at least 60 minutes
No specific food interactions. Avoid excessive intake of calcium or vitamin D supplements unless prescribed. Maintain adequate hydration.
Food, beverages other than plain water, and medications significantly reduce absorption. Avoid all food, drink, and oral medications for at least 60 minutes after dose. For patient convenience, consider once-monthly dosing on the same day each month. Antacids, calcium or iron supplements, and mineral waters should be taken at least 60 minutes after BONIVA.
Pregnancy Category D. May cause fetal harm when administered to a pregnant woman. In animal reproduction studies, bisphosphonates cause fetal skeletal retardation and decreased fetal weight. There is no adequate and well-controlled study in pregnant women; however, postmarketing reports indicate fetal skeletal abnormalities (e.g., shortened long bones) when bisphosphonates are used during pregnancy. First trimester exposure may be associated with neonatal hypocalcemia and skeletal effects. Second and third trimester exposure may increase risk for fetal skeletal mineralization defects.
FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations at oral doses up to 10 mg/kg/day but maternal toxicity and reduced fetal weight occurred. Human data: insufficient. Theoretical risk of fetal skeletal abnormalities if used in pregnancy. Avoid use during pregnancy, especially in the second and third trimesters due to potential bone development interference.
It is not known whether pamidronate is excreted in human milk. The M/P ratio is unknown. Due to potential for skeletal toxicity and hypocalcemia in the nursing infant, advise women not to breastfeed during treatment and for a period after the last dose (at least 1-2 weeks based on half-life).
Ibandronate is excreted in rat milk at concentrations 0.9 times maternal plasma levels. Human data: unknown. Risk to infant: potential for hypocalcemia and gastrointestinal irritation. Use during breastfeeding only if clearly needed and consider monitoring infant serum calcium. M/P ratio: not established in humans.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic data. However, physiological changes in pregnancy (increased plasma volume, renal clearance) may reduce drug exposure; nevertheless, because risk outweighs benefit, use is contraindicated. If used despite risk, consider monitoring serum calcium and adjusting dose based on serum calcium response and renal function, but no standard pharmacokinetic-based dosing exists.
Pharmacokinetic changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) may reduce ibandronate exposure, but no established dose adjustment. Due to teratogenicity and lack of data, avoid use during pregnancy. If inadvertently used, no specific dose adjustment is recommended; however, monitor for hypocalcemia and consider discontinuation. No dosage adjustment postpartum is required.
Monitor serum calcium, phosphate, and magnesium regularly. Aredia (pamidronate) is contraindicated in severe renal impairment (Cr Cl <30 m L/min). Administer as a slow IV infusion (over at least 2 hours for 90 mg dose; 4 hours for metastatic bone disease) to reduce risk of nephrotoxicity. Hydrate adequately before infusion. Assess for osteonecrosis of the jaw (ONJ) and perform dental exam before therapy. Not recommended in pregnancy and lactation.
Administer on an empty stomach, first thing in the morning, with a full glass of plain water (6-8 oz). Patient must remain upright for at least 60 minutes after dosing to reduce esophageal irritation. Monitor serum calcium, phosphate, and vitamin D levels prior to initiation and periodically. Contraindicated in severe renal impairment (Cr Cl <30 m L/min). Discontinue if severe musculoskeletal pain occurs.
You must have regular blood tests to monitor calcium, phosphate, and magnesium levels.,Report any bone pain, jaw pain, or swelling in your mouth immediately.,Maintain good oral hygiene and undergo a dental check-up before starting treatment.,Drink plenty of fluids before and after each infusion.,This drug is not safe during pregnancy; use effective contraception if applicable.
Take tablet immediately after waking up with a full glass of plain water, at least 60 minutes before any food, drink, or other medications.,Do not chew, suck, or crush the tablet; swallow it whole.,Stay upright (sitting or standing) for at least 60 minutes after taking the tablet to prevent esophageal irritation.,If you miss a dose, skip it and resume the next morning; do not take two doses on the same day.,Ensure adequate intake of calcium and vitamin D as directed by your physician.,Report sudden thigh or groin pain, or jaw pain with loose teeth, as these may indicate rare adverse effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AREDIA vs BONIVA, answered by our medical review team.
AREDIA is a Bisphosphonate that works by Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.. BONIVA is a Bisphosphonate that works by Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AREDIA and BONIVA depend on the specific clinical indication. These are both Bisphosphonate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AREDIA is: 90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.. The standard adult dose of BONIVA is: 150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AREDIA and BONIVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AREDIA is classified as Category C. Pregnancy Category D. May cause fetal harm when administered to a pregnant woman. In animal reproduction studies, bisphosphonates cause fetal skeletal retardation and decreased fet. BONIVA is classified as Category C. FDA Pregnancy Category C. In pregnant rats, intravenous ibandronate at doses ≥1 mg/kg/day caused fetal skeletal malformations, especially in the skull. In rabbits, no malformations. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.